# A Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy Children Aged 12 Months to 12 Years

> **NCT07054099** · PHASE3 · RECRUITING · sponsor: **GC Biopharma Corp** · enrollment: 474 (estimated)

## Conditions studied

- Varicella (Chickenpox)
- Chickenpox Vaccine

## Interventions

- **BIOLOGICAL:** MG1111 (Barycela inj.)
- **BIOLOGICAL:** VARIVAX™

## Key facts

- **NCT ID:** NCT07054099
- **Lead sponsor:** GC Biopharma Corp
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-17
- **Primary completion:** 2027-08
- **Final completion:** 2036-07
- **Target enrollment:** 474 (ESTIMATED)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07054099

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07054099, "A Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy Children Aged 12 Months to 12 Years". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07054099. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*